Because SCLC is not characterized by mutations or aberrant activity of canonical RAS signaling (27), and because MAP3K2 can alternatively regulate other downstream signaling such as the MEK5–ERK5 pathway recently implicated in SCLC pathogenesis (28–30), we aimed to analyze potential SMYD3-dependent MAP3K2 oncogenic signaling in SCLC cells. Here, MAP3K2 is linked to small cell lung carcinoma.